Related Experiment Video
Updated: Jul 20, 2026
11:29
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Summary
Hairy cell leukemia, a rare B-cell cancer, can be effectively treated with pentostatin or cladribine, leading to normal life expectancy for most patients. Alternative therapies are available for a small subset requiring further intervention.
Area of Science:
- Hematology
- Oncology
Background:
- Hairy cell leukemia is a rare, indolent B-cell malignancy.
- Standard treatments offer durable remissions and normal life expectancy for the majority of patients.
Purpose of the Study:
- To summarize the treatment landscape and prognostic factors in hairy cell leukemia.
- To highlight the efficacy of purine analog nucleoside therapies.
Main Methods:
- Review of existing literature on hairy cell leukemia treatment.
- Analysis of outcomes associated with pentostatin and cladribine therapies.
- Evaluation of alternative treatment modalities.
Main Results:
- Pentostatin and cladribine induce complete and durable remissions in most hairy cell leukemia patients.
- The majority of treated patients achieve normal life expectancy.
- A minority may require second-line treatments such as monoclonal antibodies or immunotoxins.
Conclusions:
- First-line treatment with pentostatin or cladribine is highly effective for hairy cell leukemia.
- Achieving a complete response to initial therapy is associated with the best prognosis.
- Alternative treatments exist for refractory or relapsed cases.
Related Concept Videos
01:06Multipotency and Niche of Bulge Stem Cell
A hair follicle or HF is a small part of the skin that produces the hair shaft. Paul Gerson Unna was the first to observe a bulge in the human hair follicle's outer root sheath (ORS). The bulge is present between the sebaceous gland and the arrector pili muscle and is the niche for hair follicle stem cells (HFSCs). The bulge is also a niche for melanocyte stem cells, and their loss results in graying of hair. The HFSCs express Sox9 and Lhx2, which help them maintain stemness and prevent...
01:27Disorders of Leukocytes
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...